“The Basque Country is a European leader in biosciences and the manufacture of advanced therapies”

The Deputy Minister for Technology, Innovation and Digital Transformation of the Basque Government, Jaione Ganzarain, has stated that ‘the acquisition of Syngoi Technologies by Artis BioSolutions, an international platform for the development and manufacture of advanced therapies based in the United States, reinforces our position as a leading country in Europe in the field of biosciences and the manufacture of advanced therapies’.

Ganzarain emphasised that Syngoi Technologies has developed a pioneering synthetic DNA platform based on enzymatic processes, capable of resolving one of the main bottlenecks in gene and cell therapies: the efficient, scalable and reliable production of critical materials compared to traditional models. ‘This operation will now take this technology to a new dimension, giving it industrial scale, operational robustness and international reach,’ he said.

In the opinion of the Deputy Minister, ‘it is particularly important for the Basque Government that the world’s leading companies in the field of advanced therapies are committed to investing in companies developed in the Basque Country, provided that this is accompanied by the maintenance and strengthening of industrial and scientific activity in the region’. She emphasised that this commitment is fully met in this operation.

As confirmed by the project promoters, Syngoi Technologies will maintain and strengthen its scientific and industrial base in Bilbao, consolidating investment in equipment, scientific capabilities and GMP-ready industrial facilities. This fact, in the words of Ganzarain, ‘underlines the company’s roots in the Basque Country and its contribution to the creation of skilled jobs, the attraction and retention of talent and the development of strategic industrial capabilities’.

The Deputy Minister also highlighted the evolution of the biotechnology sector in the Basque Country, which continues to grow steadily, especially in the Technology Parks. In the last four years, the number of companies in the fields of pharmaceuticals, biohealth, advanced therapies and biotechnology has grown from around 100 to more than 130, employing more than 3,000 people and with a consolidated turnover exceeding €500 million at the end of 2024.

“Operations such as this demonstrate that the Basque Country is capable of generating, scaling up and retaining high added-value biotechnology projects that are integrated into global value chains. They also reinforce the Basque Government’s commitment to creating an environment conducive to innovation and advanced manufacturing through institutional support policies and programmes that promote industrial and technological development in the region,” he concluded.